NeoGenomics appoints Jack Kenny to board; Dr. Alison Hannah departs after 10 years

NEOGENOMICS INC

Dr. Alison Hannah resigns from NeoGenomics board effective Dec 31, 2025, after over 10 years of service.
Jack Kenny appointed to board effective Jan 1, 2026; former CEO of Meridian Bioscience (taken private 2023).
Mr. Kenny brings 30+ years of diagnostics and lab services experience; also serves on Orasure, DCN, Quantum-SI boards.
Mr. Kenny's compensation is consistent with NeoGenomics' director compensation plan as disclosed in 2025 proxy.
No related-party transactions involving Mr. Kenny requiring disclosure under Item 404(a).

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.